Scienion said this week that it will provide protein microarray batches of more than 1,000 arrays to Protagen for that company's clinical validation studies of its protein biomarker panels.
According to Protagen chief scientific officer Peter Schulz-Knappe, the microarray batches will be used in "multicenter, clinical validation studies" of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.